A new study suggests that circulating IgG antibodies may help slow the growth and spread of pancreatic ductal adenocarcinoma (PDAC) by maintaining the tumor’s surrounding tissue and supporting anti-cancer immune responses.
Using genetically engineered mouse models, researchers found that mice lacking circulating antibodies developed pancreatic tumors twice as fast and survived only about half as long as normal mice. They also had more aggressive tumors, increased liver metastases, and greater invasion into nearby nerves and blood vessels.
The study showed that IgG antibodies accumulate in the tumor’s surrounding connective tissue rather than attaching directly to cancer cells. Without these antibodies, the protective extracellular matrix became less dense, making it easier for cancer cells to spread.
Antibody deficiency also reshaped the tumor immune environment, increasing immune-suppressing cells while reducing cancer-fighting T cells and natural killer (NK) cells.
The findings reveal a previously unknown role for IgG antibodies in pancreatic cancer and suggest that preserving antibody function may help limit tumor progression and metastasis while supporting future treatment strategies.